Research and Clinical Trials

Brief Description  
The purpose of this study is to assess the maintenance of efficacy of LY2216684 compared with placebo as add on therapy to SSRI among patients with Major Depressive Disorder and patients with partial response to SSRI treatment that met the remission criterion with add on LY2216684 during open-label treatment.
Who may be Eligible  
Male or female 18 to 65 with a diagnosis of Major Depressive Disorder
Major Depressive Disorder
IRB Number  
Principal Investigator  
Tcheremissine, Oleg

For More Information, Contact  Dineen  , Gardner
Phone:  (704) 446-7511  Fax:  (704) 446-7505  
Address:465 North Wendover Road Charlotte, NC 28211